U 95666E

01/01/2018 - "This method could be applied in the asymmetric synthesis of the important intermediates used in the enantioselective synthesis of the potential agent Sumanirole for the treatment of Parkinson's disease and of the potentially interesting positive inotropic agent (S)-903."
03/01/2007 - "Given data published in Parkinson's disease, the dose range of sumanirole selected here may have been too low. "
07/01/1997 - "6. In conclusion, U-95666E may have potential for the treatment of Parkinson's Disease and associated anxiety."
03/15/2007 - "A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease."
03/15/2007 - "Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease."

07/01/2021 - "Then, we explored the safety and efficacy of DA, fenoldopam (FNP, a selective D1R agonist) and sumanirole (SMR, a selective D2R agonist) in reversing BLM-induced pulmonary fibrosis. "

03/01/2007 - "Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study."
03/01/2007 - "To compare the efficacy, safety and tolerability of sumanirole with placebo in patients with idiopathic restless legs syndrome (RLS). "

01/01/2023 - "Both SKF82958 and sumanirole induced dyskinesia, although with significant differences in temporal course, overall severity, and body distribution. "
01/01/2023 - "Abnormal involuntary movements were elicited by the D1 agonist SKF82958 or the D2 agonist sumanirole, while overall motor activity was quantified using video analysis (DeepLabCut). "
09/01/2005 - "Dyskinesias were present with L-DOPA treatment but were not observed in sumanirole-, ropinirole-, or placebo-treated primates. "

01/01/2020 - "Importantly, VU0255035 (10 mg/kg) potentiated the antiparkinsonian-like effects (i.e., increased locomotor activity and decreased catalepsy) of an ineffective sumanirole dose (3 mg/kg). "
01/01/2018 - "Locomotor activity, pre-pulse inhibition (PPI) and drug-induced catalepsy were then evaluated in wild-type, A2A R and D2 R knock-out mice, with and without the concomitant administration of either the D2 R agonist sumanirole or the A2A R antagonist SCH442416. "